Motus GI to Present Clinical Results from REDUCE Study Evaluating the Pure-Vu® System at Digestive Disease Week® 2019

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Motus
GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a
medical technology company dedicated to improving clinical outcomes and
enhancing the cost-efficiency of colonoscopy, announced today that full
clinical results from the Company’s REDUCE (“Reliable
Endoscopic Diagnosis
Utilizing Cleansing
Enhancement”) study evaluating the Pure-Vu®
System will be presented at Digestive
Disease Week® 2019 (“DDW”), being held May 18 – 21, 2019 in San
Diego, CA. The data being presented at DDW is embargoed until the time
of presentation.

The
Pure-Vu® System is a U.S. Food and Drug Administration (“FDA”)
cleared medical device indicated to help facilitate the cleaning of a
poorly prepared colon during the colonoscopy procedure. The device
integrates with standard and slim colonoscopes to enable safe and rapid
cleansing during the procedure while preserving established procedural
workflow and techniques.

Details of the poster presentation are as follows:

Title: Evaluation of Bowel Cleansing Efficacy in Hospitalized
Patient Population Using the Pure-Vu® System 
Presenting
Author: Vladimir Kushnir, M.D. 
Abstract #: MO1658 
Date
and Time: May 20, 2019 at 12:00 p.m. PDT 
Session
Title: Lower GI 2

Following the presentation, the poster will be available on Motus GI’s website
in the Pure-Vu®
Publications section.

Motus GI will also have a booth at DDW located in the Exhibit Hall at
Booth #4315.

About Digestive Disease Week®

Digestive Disease Week® (DDW) is the largest international gathering of
physicians, researchers and academics in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by
the American Association for the Study of Liver Diseases (AASLD), the
American Gastroenterological Association (AGA) Institute, the American
Society for Gastrointestinal Endoscopy (ASGE) and the Society for
Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21, 2019,
at the San Diego Convention Center. The meeting showcases more than
5,000 abstracts and hundreds of lectures on the latest advances in GI
research, medicine and technology. More information can be found at www.ddw.org.

About Motus GI and the Pure-Vu® System

Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving clinical
outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s
flagship product is the Pure-Vu^® System, a U.S. FDA cleared
medical device indicated to help facilitate the cleaning of a poorly
prepared colon during the colonoscopy procedure. The device integrates
with standard and slim colonoscopes to enable safe and rapid cleansing
during the procedure while preserving established procedural workflow
and techniques. The Pure-Vu^® System has received CE mark
approval in Europe. The Pure-Vu^® System is currently being
introduced on a pilot basis in the U.S. market, and the Company is
planning to initiate a full commercial launch focused on the inpatient
colonoscopy market in the U.S. and select international markets in 2019.
Challenges with bowel preparation for inpatient colonoscopy represent a
significant area of unmet need that directly affects clinical outcomes
and increases the cost of care in a market segment that comprises
approximately 1.5 million annual procedures in the U.S. and
approximately 4 million annual procedures worldwide. Motus GI believes
the Pure-Vu^® System may improve outcomes and lower costs for
hospitals by reducing the time to successful colonoscopy, minimizing
delayed and incomplete procedures, and improving the quality of an exam.
In clinical studies to date, the Pure-Vu^® System
significantly increased the number of patients with an adequate
cleansing level, according to the Boston Bowel Preparation Scale Score,
a validated assessment instrument.

For more information, visit www.motusgi.com
and connect with the Company on Twitter,
LinkedIn
and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company’s current
expectations and assumptions. The Private Securities Litigation Reform
Act of 1995 provides a safe-harbor for forward-looking statements. These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,” “plan,”
“believe,” “estimate,” “potential,” “predict,” “project,” “should,”
“would” and similar expressions and the negatives of those terms,
including without limitation, risks inherent in the development and
commercialization of potential products, uncertainty in the timing and
results of clinical trials or regulatory approvals, maintenance of
intellectual property rights or other risks discussed in the Company’s
Form 10-K filed on March 26, 2019, and its other filings with the
Securities and Exchange Commission. Prospective investors are cautioned
not to place undue reliance on such forward-looking statements, which
speak only as of the date hereof. The Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise.

Contacts

Investor and Media Contact:
Jenene
Thomas
Jenene Thomas Communications, LLC
(833) 475-8247
mots@jtcir.com